Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 1508

Dr Owen O'Connor - Columbia University Medical Centre, New York, USA

Dr Owen O'Connor speaks to ecancer at ASH 2018 about the ACT-1 study, for younger patients with T-cell lymphoma.

This was a randomised comparison of patients with CHOP alone, or with CHOP alemtuzumab, both then followed by stem cell transplant.

Dr O'Connor describes outlines the final results of this study, the toxicities, and modifications which were made.

Watch his interview about ECHELON-2 here.

Related videos

follow us

Core Surgical Training

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation